Drug Profile
Research programme: neuropeptide FF receptor antagonists - Merck
Latest Information Update: 30 Aug 2011
Price :
$50
*
At a glance
- Originator Merck AG
- Class
- Mechanism of Action Neuropeptide FF receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 30 Aug 2011 No development reported for Obesity in USA (unspecified route)
- 19 Nov 2008 Early research in Obesity in USA (unspecified route)